KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Income from Continuing Operations (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Income from Continuing Operations for 13 consecutive years, with 105261000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 48.93% to 105261000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 345910000.0, a 44.54% decrease, with the full-year FY2025 number at 345910000.0, down 44.54% from a year prior.
  • Income from Continuing Operations was 105261000.0 for Q4 2025 at Xenon Pharmaceuticals, down from 90896000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 15445000.0 in Q3 2021 to a low of 105261000.0 in Q4 2025.
  • A 5-year average of 48184250.0 and a median of 44594000.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: tumbled 12533.71% in 2021, then increased 2.26% in 2023.
  • Xenon Pharmaceuticals' Income from Continuing Operations stood at 25564000.0 in 2021, then tumbled by 46.28% to 37395000.0 in 2022, then rose by 2.26% to 36549000.0 in 2023, then tumbled by 93.37% to 70676000.0 in 2024, then crashed by 48.93% to 105261000.0 in 2025.
  • Per Business Quant, the three most recent readings for XENE's Income from Continuing Operations are 105261000.0 (Q4 2025), 90896000.0 (Q3 2025), and 84706000.0 (Q2 2025).